For example, DCZ3112 effectively inhibited tumor growth in HER2-positive xenograft models with minimal systemic toxicity.57 Similarly, FW-04-806 showed selective activity against HER2-overexpressing tumors and low toxicity in treated animals.73 Okicamelliaside also demonstrated high antitumor efficacy in A549 xenografts while maintaining excellent tolerability.37 The reduced toxicity of these agents is attributed to their focused degradation of oncogenic kinase clients, avoiding the global disturbance of protein homeostasis that characterizes pan-Hsp90 inhibition. This evidence concerns the gene ERBB2 and neoplasm.